H2N2V1, Ncbi, Merge, bibRecord, 000893

Molecular basis of live-attenuated influenza virus.

Identifieur interne : 000893 ( Ncbi/Merge ); précédent : 000892; suivant : 000894

Molecular basis of live-attenuated influenza virus.

Auteurs : Wen He [République populaire de Chine] ; Wei Wang ; Huamin Han ; Lei Wang ; Ge Zhang ; Bin Gao

Source :

PloS one [ 1932-6203 ] ; 2013.

RBID : pubmed:23555969

Descripteurs français

KwdFr :
- ARN viral (génétique), Animaux, Grippe humaine (), Grippe humaine (virologie), Humains, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (virologie), Lignée cellulaire, Mutation, Protéines virales (génétique), RNA replicase (génétique), Régulation de l'expression des gènes viraux, Souris, Souris de lignée C57BL, Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (physiologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (usage thérapeutique), Vaccins atténués (génétique), Vaccins atténués (usage thérapeutique).
MESH :
- génétique : ARN viral, Protéines virales, RNA replicase, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués.
- physiologie : Sous-type H1N1 du virus de la grippe A.
- usage thérapeutique : Vaccins antigrippaux, Vaccins atténués.
- virologie : Grippe humaine, Infections à Orthomyxoviridae.
- Animaux, Grippe humaine, Humains, Infections à Orthomyxoviridae, Lignée cellulaire, Mutation, Régulation de l'expression des gènes viraux, Souris, Souris de lignée C57BL.

English descriptors

KwdEn :
- Animals, Cell Line, Gene Expression Regulation, Viral, Humans, Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (physiology), Influenza Vaccines (genetics), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Influenza, Human (virology), Mice, Mice, Inbred C57BL, Mutation, Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), RNA Replicase (genetics), RNA, Viral (genetics), Vaccines, Attenuated (genetics), Vaccines, Attenuated (therapeutic use), Viral Proteins (genetics).
MESH :
- chemical , genetics : Influenza Vaccines, RNA Replicase, RNA, Viral, Vaccines, Attenuated, Viral Proteins.
- genetics : Influenza A Virus, H1N1 Subtype.
- physiology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections.
- chemical , therapeutic use : Influenza Vaccines, Vaccines, Attenuated.
- virology : Influenza, Human, Orthomyxoviridae Infections.
- Animals, Cell Line, Gene Expression Regulation, Viral, Humans, Mice, Mice, Inbred C57BL, Mutation.

Abstract

Human influenza is a seasonal disease associated with significant morbidity and mortality. The most effective means for controlling infection and thereby reducing morbidity and mortality is vaccination with a three inactivated influenza virus strains mixture, or by intranasal administration of a group of three different live attenuated influenza vaccine strains. Comparing to the inactivated vaccine, the attenuated live viruses allow better elicitation of a long-lasting and broader immune (humoral and cellular) response that represents a naturally occurring transient infection. The cold-adapted (ca) influenza A/AA/6/60 (H2N2) (AA ca) virus is the backbone for the live attenuated trivalent seasonal influenza vaccine licensed in the United States. Similarly, the influenza A components of live-attenuated vaccines used in Russia have been prepared as reassortants of the cold-adapted (ca) H2N2 viruses, A/Leningrad/134/17/57-ca (Len/17) and A/Leningrad/134/47/57-ca (Len/47) along with virulent epidemic strains. However, the mechanism of temperature-sensitive attenuation is largely elusive. To understand how modification at genetic level of influenza virus would result in attenuation of human influenza virus A/PR/8/34 (H1N1,A/PR8), we investigated the involvement of key mutations in the PB1 and/or PB2 genes in attenuation of influenza virus in vitro and in vivo. We have demonstrated that a few of residues in PB1 and PB2 are critical for the phenotypes of live attenuated, temperature sensitive influenza viruses by minigenome assay and real-time PCR. The information of these mutation loci could be used for elucidation of mechanism of temperature-sensitive attenuation and as a new strategy for influenza vaccine development.

DOI: 10.1371/journal.pone.0060413
PubMed: 23555969

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000124
to stream PubMed, to step Curation: 000124
to stream PubMed, to step Checkpoint: 000114

Links to Exploration step

pubmed:23555969

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular basis of live-attenuated influenza virus.</title>
<author><name sortKey="He, Wen" sort="He, Wen" uniqKey="He W" first="Wen" last="He">Wen He</name>
<affiliation wicri:level="3"><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Han, Huamin" sort="Han, Huamin" uniqKey="Han H" first="Huamin" last="Han">Huamin Han</name>
</author>
<author><name sortKey="Wang, Lei" sort="Wang, Lei" uniqKey="Wang L" first="Lei" last="Wang">Lei Wang</name>
</author>
<author><name sortKey="Zhang, Ge" sort="Zhang, Ge" uniqKey="Zhang G" first="Ge" last="Zhang">Ge Zhang</name>
</author>
<author><name sortKey="Gao, Bin" sort="Gao, Bin" uniqKey="Gao B" first="Bin" last="Gao">Bin Gao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23555969</idno>
<idno type="pmid">23555969</idno>
<idno type="doi">10.1371/journal.pone.0060413</idno>
<idno type="wicri:Area/PubMed/Corpus">000124</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000124</idno>
<idno type="wicri:Area/PubMed/Curation">000124</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000124</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000114</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000114</idno>
<idno type="wicri:Area/Ncbi/Merge">000893</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Molecular basis of live-attenuated influenza virus.</title>
<author><name sortKey="He, Wen" sort="He, Wen" uniqKey="He W" first="Wen" last="He">Wen He</name>
<affiliation wicri:level="3"><nlm:affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Han, Huamin" sort="Han, Huamin" uniqKey="Han H" first="Huamin" last="Han">Huamin Han</name>
</author>
<author><name sortKey="Wang, Lei" sort="Wang, Lei" uniqKey="Wang L" first="Lei" last="Wang">Lei Wang</name>
</author>
<author><name sortKey="Zhang, Ge" sort="Zhang, Ge" uniqKey="Zhang G" first="Ge" last="Zhang">Ge Zhang</name>
</author>
<author><name sortKey="Gao, Bin" sort="Gao, Bin" uniqKey="Gao B" first="Bin" last="Gao">Bin Gao</name>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Gene Expression Regulation, Viral</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (physiology)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mutation</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>RNA Replicase (genetics)</term>
<term>RNA, Viral (genetics)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Vaccines, Attenuated (therapeutic use)</term>
<term>Viral Proteins (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (génétique)</term>
<term>Animaux</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (virologie)</term>
<term>Lignée cellulaire</term>
<term>Mutation</term>
<term>Protéines virales (génétique)</term>
<term>RNA replicase (génétique)</term>
<term>Régulation de l'expression des gènes viraux</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (physiologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Vaccins atténués (génétique)</term>
<term>Vaccins atténués (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
<term>RNA Replicase</term>
<term>RNA, Viral</term>
<term>Vaccines, Attenuated</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term>
<term>Protéines virales</term>
<term>RNA replicase</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Gene Expression Regulation, Viral</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mutation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae</term>
<term>Lignée cellulaire</term>
<term>Mutation</term>
<term>Régulation de l'expression des gènes viraux</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Human influenza is a seasonal disease associated with significant morbidity and mortality. The most effective means for controlling infection and thereby reducing morbidity and mortality is vaccination with a three inactivated influenza virus strains mixture, or by intranasal administration of a group of three different live attenuated influenza vaccine strains. Comparing to the inactivated vaccine, the attenuated live viruses allow better elicitation of a long-lasting and broader immune (humoral and cellular) response that represents a naturally occurring transient infection. The cold-adapted (ca) influenza A/AA/6/60 (H2N2) (AA ca) virus is the backbone for the live attenuated trivalent seasonal influenza vaccine licensed in the United States. Similarly, the influenza A components of live-attenuated vaccines used in Russia have been prepared as reassortants of the cold-adapted (ca) H2N2 viruses, A/Leningrad/134/17/57-ca (Len/17) and A/Leningrad/134/47/57-ca (Len/47) along with virulent epidemic strains. However, the mechanism of temperature-sensitive attenuation is largely elusive. To understand how modification at genetic level of influenza virus would result in attenuation of human influenza virus A/PR/8/34 (H1N1,A/PR8), we investigated the involvement of key mutations in the PB1 and/or PB2 genes in attenuation of influenza virus in vitro and in vivo. We have demonstrated that a few of residues in PB1 and PB2 are critical for the phenotypes of live attenuated, temperature sensitive influenza viruses by minigenome assay and real-time PCR. The information of these mutation loci could be used for elucidation of mechanism of temperature-sensitive attenuation and as a new strategy for influenza vaccine development.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23555969</PMID>
<DateCompleted><Year>2013</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<Issue>3</Issue>
<PubDate><Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular basis of live-attenuated influenza virus.</ArticleTitle>
<Pagination><MedlinePgn>e60413</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0060413</ELocationID>
<Abstract><AbstractText>Human influenza is a seasonal disease associated with significant morbidity and mortality. The most effective means for controlling infection and thereby reducing morbidity and mortality is vaccination with a three inactivated influenza virus strains mixture, or by intranasal administration of a group of three different live attenuated influenza vaccine strains. Comparing to the inactivated vaccine, the attenuated live viruses allow better elicitation of a long-lasting and broader immune (humoral and cellular) response that represents a naturally occurring transient infection. The cold-adapted (ca) influenza A/AA/6/60 (H2N2) (AA ca) virus is the backbone for the live attenuated trivalent seasonal influenza vaccine licensed in the United States. Similarly, the influenza A components of live-attenuated vaccines used in Russia have been prepared as reassortants of the cold-adapted (ca) H2N2 viruses, A/Leningrad/134/17/57-ca (Len/17) and A/Leningrad/134/47/57-ca (Len/47) along with virulent epidemic strains. However, the mechanism of temperature-sensitive attenuation is largely elusive. To understand how modification at genetic level of influenza virus would result in attenuation of human influenza virus A/PR/8/34 (H1N1,A/PR8), we investigated the involvement of key mutations in the PB1 and/or PB2 genes in attenuation of influenza virus in vitro and in vivo. We have demonstrated that a few of residues in PB1 and PB2 are critical for the phenotypes of live attenuated, temperature sensitive influenza viruses by minigenome assay and real-time PCR. The information of these mutation loci could be used for elucidation of mechanism of temperature-sensitive attenuation and as a new strategy for influenza vaccine development.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Wen</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Huamin</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Lei</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Ge</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>03</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C057027">PB2 protein, Influenzavirus A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C077346">influenza virus polymerase basic protein 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber>
<NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>10</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23555969</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0060413</ArticleId>
<ArticleId IdType="pii">PONE-D-12-33096</ArticleId>
<ArticleId IdType="pmc">PMC3608614</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vopr Virusol. 2001 May-Jun;46(3):5-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11450146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1999 Feb 1;254(1):50-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9927573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2002 Jul;110(1):9-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12093881</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Feb 1;306(1):18-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12620793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2004;283:43-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15298167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1984 Feb;43(2):457-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6693167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1984 Jun;44(3):730-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6724694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1985 Oct;135(4):2800-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2411815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jan 8;25(4):612-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17005299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2009 Apr;8(4):401-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19348557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):193-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19644442</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Dec 1;183(11):6883-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19923474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(2):e9025</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20140252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2010 Sep 10;285(37):28411-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20538599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(10):e13755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21060780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2010 Nov 18;363(21):2036-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21083388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2010 Dec;9(12):1423-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21105778</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Jan;85(1):76-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20962087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2011 Apr 10;412(2):297-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21315402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2011;8:538</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22168277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2004 Nov;23(11):1053-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15545863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2000 Feb;38(2):839-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10655394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 Nov;81(Pt 11):2689-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11038381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1995 Jun;76 ( Pt 6):1521-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7782782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1995 Oct;69(10):5969-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7666501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1996 Sep;77 ( Pt 9):2149-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8811014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1997 Aug;176 Suppl 1:S45-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9240694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Epidemiol. 1997 Jul;13(5):591-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9258574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Gao, Bin" sort="Gao, Bin" uniqKey="Gao B" first="Bin" last="Gao">Bin Gao</name>
<name sortKey="Han, Huamin" sort="Han, Huamin" uniqKey="Han H" first="Huamin" last="Han">Huamin Han</name>
<name sortKey="Wang, Lei" sort="Wang, Lei" uniqKey="Wang L" first="Lei" last="Wang">Lei Wang</name>
<name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
<name sortKey="Zhang, Ge" sort="Zhang, Ge" uniqKey="Zhang G" first="Ge" last="Zhang">Ge Zhang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="He, Wen" sort="He, Wen" uniqKey="He W" first="Wen" last="He">Wen He</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000893 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000893 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:23555969
   |texte=   Molecular basis of live-attenuated influenza virus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:23555969" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Molecular basis of live-attenuated influenza virus.

Molecular basis of live-attenuated influenza virus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki